华东医药：HDM1002体重管理适应症3期临床研究设置了200mg、400mg及安慰剂三个剂量组

Core Viewpoint - The company is conducting a Phase 3 clinical trial for HDM1002, focusing on weight management, with a planned duration of 56 weeks to assess the efficacy and safety of different dosage groups [1] Group 1: Clinical Trial Details - The Phase 3 clinical study for HDM1002 includes three dosage groups: 200mg, 400mg, and a placebo [1] - The treatment period is set for 52 weeks, followed by a 4-week safety follow-up, totaling 56 weeks [1] - The topline results are expected to be available in Q4 2026 after unblinding [1] Group 2: Comparison with Competitors - An investor raised a question regarding the duration of the highest dosage trial for HDM1002 compared to Eli Lilly's latest weight loss drug, which had longer trial durations of 36 weeks and 72 weeks for its Phase 2 and Phase 3 studies respectively [1]